SOD1 Transgenic Mouse Model Development Service

Are you currently facing long drug development cycles, difficulty in validating therapeutic targets, or challenges in preclinical efficacy for Amyotrophic Lateral Sclerosis (ALS)? Our SOD1 transgenic mouse models service helps you accelerate drug discovery and validate therapeutic efficacy through highly predictive and robust preclinical platforms. Our advanced animal modeling and comprehensive phenotyping techniques provide unparalleled insights into disease progression and therapeutic impact.

ALS is a devastating neurodegenerative disorder characterized by progressive motor neuron loss. A significant portion of familial ALS cases are linked to mutations in the superoxide dismutase 1 (SOD1) gene. These mutations confer a toxic gain-of-function, leading to protein misfolding and aggregation, which drives motor neuron degeneration. The development of SOD1 transgenic mouse models, particularly the SOD1-G93A strain, has revolutionized ALS research by faithfully recapitulating key human disease pathologies, making them indispensable tools for understanding disease mechanisms and evaluating therapeutic interventions.

How Our SOD1 Transgenic Mouse Models Can Assist Your Project?

At Creative Biolabs, we provide comprehensive solutions to advance your ALS research. Our SOD1 transgenic mouse models serve as a gold standard for preclinical efficacy testing, enabling precise mechanism of action studies and robust biomarker validation. You can expect clear deliverables, including detailed insights into compound effects on survival, motor function, oxidative stress, and neuroinflammation. We are committed to delivering actionable data that directly informs your therapeutic development decisions.

Discover How We Can Help - Request a Consultation

Workflow:

Our streamlined workflow ensures a clear, efficient, and scientifically rigorous process for every project, designed for seamless collaboration and optimal outcomes.

• Required Starting Materials:

To initiate your project, we typically require:

1. Compound Details: Comprehensive information on your therapeutic compound, including its chemical structure, proposed mechanism of action, and any existing in vitro or preliminary in vivo data.
2. Study Objectives: A clear outline of your research goals, such as assessing compound efficacy, evaluating pharmacokinetic/pharmacodynamic (PK/PD) profiles, or elucidating specific disease mechanisms.
3. Desired Endpoints: Specification of the key readouts and measurements most relevant to your therapeutic hypothesis (e.g., survival, motor function, specific biochemical markers).

• Final Deliverables:

Upon project completion, you will receive:

1. Comprehensive Study Report: A detailed document summarizing all experimental procedures, results, statistical analyses, and conclusions.
2. Raw Data Files: Complete raw data sets from all in-life and ex vivo measurements, provided in a user-friendly format for your own analysis.
3. Histological Images/Slides: High-resolution images or prepared tissue slides from key regions of interest, showcasing pathological changes and therapeutic effects.

• Estimated Timeframe:

The typical timeframe for a comprehensive SOD1 efficacy study ranges from 16 to 24 weeks, depending on the specific SOD1 model selected (e.g., high-copy vs. low-copy), the duration of treatment, and the complexity of the desired endpoints.

Why Choose Us?

Choosing CBL for your SOD1 transgenic mouse model research means partnering with a leader in neurodegenerative disease preclinical studies. With over two decades of specialized experience, we offer unparalleled scientific rigor, customized solutions, and a proven track record of success. Our state-of-the-art facilities and commitment to ethical research (the 3Rs: Replacement, Reduction, Refinement) ensure the highest quality data and animal welfare. We provide comprehensive phenotyping, from precise behavioral assessments to intricate molecular and histological analyses, giving you a holistic understanding of disease progression and therapeutic impact.

Experience the CBL Advantage - Get a Quote Today

SOD1 Transgenic Mouse Models

The discovery of mutations in the human SOD1 gene in familial ALS patients paved the way for the creation of the first transgenic mouse models in 1994. These models, most notably the SOD1-G93A transgenic mouse, carry the human SOD1 gene with a specific mutation (glycine to alanine at position 93) and overexpress the mutant protein. This overexpression leads to a toxic gain-of-function, rather than a loss of the enzyme's normal antioxidant activity, which is believed to be the primary driver of pathology.

Fig.1 Longitudinal grip strength measurement of SOD1-G93A mice.

Customer Reviews

[Predictive Efficacy] "Using CBL's SOD1 transgenic mouse models in our research has significantly improved our ability to predict compound efficacy, allowing us to prioritize the most promising candidates for clinical development. The detailed behavioral and pathological readouts provided a comprehensive understanding of drug impact, far beyond what we could achieve in-house. We particularly appreciate the meticulous attention to animal welfare and the robust statistical power of their studies." - Dr. A***n, Senior Scientist, 2024.

[Mechanism Elucidation] "CBL's expertise in SOD1 models facilitated a deeper understanding of the neuroinflammatory mechanisms underlying our therapeutic's action. Their comprehensive histological analysis and biomarker profiling were instrumental in elucidating the precise cellular targets, which was crucial for refining our drug's strategy. Their team's responsiveness and scientific rigor are unparalleled." - Dr. S***h, Head of Neurobiology, 2023.

[Accelerated Timelines] "We faced challenges with long lead times for our preclinical ALS studies. CBL's efficient workflow and readily available SOD1-G93A cohorts significantly accelerated our project timelines, cutting our experimental phase by nearly 30%. The quality of data and the clear, concise reporting allowed for swift decision-making. Their guidance on experimental design was also invaluable in optimizing our resource allocation." - Dr. M***a, Director of Preclinical Development, 2024.

What we can offer

• Comprehensive Preclinical Solutions: CBL offers a one-stop service for SOD1 transgenic mouse model studies, encompassing everything from initial consultation and model selection to in-life monitoring, comprehensive endpoint analysis, and detailed reporting, ensuring a seamless research experience.
• Customized Study Design & Execution: We provide highly flexible and customized study designs tailored to your unique research objectives, compound characteristics, and desired outcomes. Whether you need specific dosing regimens, novel endpoints, or a particular SOD1 strain, CBL's experts will craft a protocol optimized for your project.
• Robust Model Validation & Stability: Our SOD1 transgenic mouse colonies are meticulously maintained and rigorously validated to ensure consistent disease progression and phenotypic stability across cohorts, guaranteeing reliable and reproducible results for your studies.
• Advanced Phenotyping & Quality Control: We utilize state-of-the-art behavioral, histological, and biochemical techniques for comprehensive phenotyping, including advanced motor function assessments and precise quantification of pathological markers. Our high-standard quality control tools are applied throughout the process to quantify and evaluate the quality of all data and samples.
• Expert Scientific Consultation: Benefit from our over 20 years of specialized experience in neurodegenerative disease research. Our scientific team provides expert guidance on experimental design, data interpretation, and strategic planning to maximize the impact of your preclinical studies.
• Ethical & Compliant Research: CBL operates under a well-established quality system, adhering to strict ethical guidelines and regulatory standards for animal welfare. We implement robust aseptic verification procedures and follow Good Laboratory Practice (GLP) principles where applicable, ensuring the integrity and credibility of your research.

Related Services

To further support your comprehensive neurodegenerative disease research goals, CBL offers a suite of complementary services and model variations:

• Other Neurodegenerative Disease Models: Explore our extensive portfolio of preclinical models for Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, and other neurological disorders.
• In Vitro ALS Models: Complement your in vivo studies with our advanced in vitro platforms, including iPSC-derived motor neuron cultures and co-culture systems, for high-throughput screening and mechanistic investigations.
• Biomarker Discovery & Validation Services: Leverage our expertise in identifying and validating novel biomarkers for disease progression and therapeutic response, crucial for translational success.

Creative Biolabs is your comprehensive partner in neurodegenerative disease research, offering integrated solutions to accelerate your discoveries.

Contact Our Team for More Information and to Discuss Your Project.